Science Explorer Back to mapMap
Discussion
Company · Marlborough · United States

Phio Pharmaceuticals (United States)

phiopharma.comROR OpenAlex
Research works
58
▲ 54% vs 2018-21
Citations
439
7.5 per fractional work
Top-10% rate
4.0%
all institutions 10.0%
Open access
52%
world 40%
International
17%
world 18%
Phio Pharmaceuticals (United States)

Not ranked overall: Phio Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Phio Pharmaceuticals (United States) work in?

In 2022-now, 51% of research at Phio Pharmaceuticals (United States) is in Life Sciences, 45% in Health Sciences. Its largest fields are Medicine (45%), Biochemistry, Genetics and Molecular Biology (36%), Immunology and Microbiology (13%). It does 2.5× the world's share of Life Sciences.

Life Sciences: 12 fractional works · 51.0% of its workBiochemistry, Genetics and Molecular Biology: 9 fractional works · 36.3% of its workMolecular Biology: 8 fractional works · 33.6% of its workBiotechnology: 0 fractional works · 1.4% of its workCell Biology: 0 fractional works · 1.4% of its workImmunology and Microbiology: 3 fractional works · 13.0% of its workImmunology: 3 fractional works · 13.0% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 1.7% of its workPharmaceutical Science: 0 fractional works · 1.4% of its workToxicology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.0% of its workHealth Sciences: 11 fractional works · 45.2% of its workMedicine: 11 fractional works · 45.2% of its workOncology: 7 fractional works · 30.8% of its workEpidemiology: 1 fractional works · 5.5% of its workPharmacology: 0 fractional works · 1.7% of its workHematology: 0 fractional works · 1.7% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 1.4% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 1.4% of its workImmunology and Allergy: 0 fractional works · 0.7% of its workSurgery: 0 fractional works · 0.7% of its workNephrology: 0 fractional works · 0.3% of its workPathology and Forensic Medicine: 0 fractional works · 0.3% of its workPhysiology: 0 fractional works · 0.3% of its workRheumatology: 0 fractional works · 0.3% of its workTransplantation: 0 fractional works · 0.3% of its workPhysical Sciences: 1 fractional works · 3.4% of its workEngineering: 1 fractional works · 3.4% of its workBiomedical Engineering: 1 fractional works · 3.4% of its workSocial Sciences: 0 fractional works · 0.3% of its workPsychology: 0 fractional works · 0.3% of its workClinical Psychology: 0 fractional works · 0.3% of its workALL ITS WORKPhioPharmaceuticals…24fractional works, 2022-now
Life Sciences51%Physical Sciences3%Health Sciences45%Social Sciences0%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 6 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology936.3%
    2. Immunology and Microbiology313.0%
    3. Pharmacology, Toxicology and Pharmaceutics01.7%
    1. Medicine1145.2%
    1. Engineering13.4%
    1. Psychology00.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 6.81× its world share, 9 worksBiochemistry, Geneti…Immunology and Microbiology: 12.90× its world share, 3 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 4.89× its world share, 0 worksPharmacology, Toxico…Engineering: 0.23× its world share, 1 worksEngineeringMedicine: 2.35× its world share, 11 worksMedicinePsychology: 0.11× its world share, 0 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 12.9×. Every wedge is a field page.

All 6 fields, with their numbers
  1. Immunology and Microbiology12.90×3 works
  2. Biochemistry, Genetics and Molecular Biology6.81×9 works
  3. Pharmacology, Toxicology and Pharmaceutics4.89×0 works
  4. Medicine2.35×11 works
  5. Engineering0.23×1 works
  6. Psychology0.11×0 works

Who are the top researchers at Phio Pharmaceuticals (United States)?

Ranked on the quality score, Simon Paul Fricker, Benjamin Cuiffo and Pamela A. Pavco lead among researchers whose main affiliation is Phio Pharmaceuticals (United States).

  1. 1 Simon Paul Fricker United States · #647,094 worldwide 6.1k citations · 127 works
  2. 2 Benjamin Cuiffo United States · #912,803 worldwide 1.4k citations · 47 works
  3. 3 Pamela A. Pavco United States · #2,140,165 worldwide 1.6k citations · 34 works
  4. 4 Andrew R. Boone United States · #2,607,008 worldwide 118 citations · 59 works
  5. 5 Brianna Rivest United States · #3,410,125 worldwide 14 citations · 18 works
  6. 6 Dingxue Yan United States · #3,744,331 worldwide 69 citations · 33 works
  7. 7 Melissa Maxwell United States · #4,080,670 worldwide 166 citations · 44 works
  8. 8 James P. Cardia United States · #4,701,210 worldwide 526 citations · 58 works
  9. 9 Karen G. Bulock United States · #5,097,391 worldwide 211 citations · 19 works
All ranked researchers at Phio Pharmaceuticals (United States)

What are the most cited papers from Phio Pharmaceuticals (United States)?

The most cited paper from Phio Pharmaceuticals (United States) is "Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3" (Yong‐Chen Lu, Linda L. Parker, Tangying Lu et al., 2017), with 280 citations. Next come "Visualization of self-delivering hydrophobically modified siRNA cellular internalization" (133) and "Rabenosyn-5 defines the fate of the transferrin receptor following clathrin-mediated endocytosis" (93).

Most cited papers
#PaperReleasedCitations
1 Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3 Yong‐Chen Lu, Linda L. Parker, Tangying Lu et al. · Journal of Clinical Oncology Open access 15 Aug 2017 280
2 Visualization of self-delivering hydrophobically modified siRNA cellular internalization Socheata Ly, Deanna M. Navaroli, Marie-Cécile Didiot et al. · Nucleic Acids Research Open access 24 Oct 2016 133
3 Rabenosyn-5 defines the fate of the transferrin receptor following clathrin-mediated endocytosis Deanna M. Navaroli, Karl D. Bellve, Clive Standley et al. · Proceedings of the National Academy of Sciences Open access 30 Jan 2012 93
4 The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event? Christopher J. Horvath, Mark Milton · Toxicologic Pathology 24 Feb 2009 87
5 Specificity and functionality of microRNA inhibitors Barbara Robertson, Andrew B Dalby, Jon M. Karpilow et al. · Silence Open access Apr 2010 81
All 41 most cited papers, with filters and sorting

Which keywords describe research at Phio Pharmaceuticals (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Cancer Immunotherapy, Immunotherapy, Tumor Regression, CAR T Cells, Chimeric Antigen Receptor, Gene Therapy, Innate Immunity and Dendritic Cells.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 25 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 25 words, with their numbers
  1. Cancer Immunotherapy7▲ 192×2 topics
  2. Immunotherapy6▲ 37×4 topics
  3. Tumor Regression5▲ 181×2 topics
  4. CAR T Cells5▲ 258×1 topic
  5. Chimeric Antigen Receptor5▲ 258×1 topic
  6. Gene Therapy3▲ 61×2 topics
  7. Dendritic Cells3▲ 119×1 topic
  8. Immunity3▲ 26×1 topic
  9. Innate Immunity3▲ 34×2 topics
  10. RNA Interference2▲ 125×1 topic
  11. siRNA Delivery2▲ 179×1 topic
  12. Cancer Therapy2▲ 16×4 topics
  13. Photodynamic Therapy2▲ 39×2 topics
  14. Transcriptional Regulation2▲ 54×2 topics
  15. BET Bromodomains2▲ 267×1 topic
  16. PROTACs2▲ 267×1 topic
  17. Tumor Microenvironment2▲ 17×2 topics
  18. Immune Checkpoint Blockade2▲ 56×1 topic
  19. PD-1 and PD-L12▲ 56×1 topic
  20. Nanoparticles2▲ 4.9×2 topics
  21. Nonmelanoma Skin Cancer1▲ 213×1 topic
  22. Skin Cancers1▲ 213×1 topic
  23. Proteasome Inhibitors1▲ 70×2 topics
  24. Tumor Targeting1▲ 26×2 topics
  25. Melanoma1▲ 66×2 topics

Which research topics does Phio Pharmaceuticals (United States) publish most on?

By volume in 2022-now: CAR-T cell therapy research, Immunotherapy and Immune Responses, RNA Interference and Gene Delivery and Protein Degradation and Inhibitors.

CAR-T cell therapy resea…5CAR-T cell therapy research: 5 fractional worksImmunotherapy and Immune Responses: 3 fractional worksRNA Interference and Gene Delivery: 2 fractional worksProtein Degradation and Inhibitors: 2 fractional worksCancer Immunotherapy and Biomarkers: 2 fractional worksNonmelanoma Skin Cancer …1Nonmelanoma Skin Cancer Studies: 1 fractional worksUbiquitin and proteasome pathways: 1 fractional worksNanoplatforms for cancer theranostics: 1 fractional worksCutaneous Melanoma Detection and Management: 1 fractional worksHistone Deacetylase Inhibitors Research: 1 fractional works
OncologyImmunologyMolecular BiologyEpidemiology1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CAR-T cell therapy research Oncology 5 works
  2. 2 Immunotherapy and Immune Responses Immunology 3 works
  3. 3 RNA Interference and Gene Delivery Molecular Biology 2 works
  4. 4 Protein Degradation and Inhibitors Molecular Biology 2 works
  5. 5 Cancer Immunotherapy and Biomarkers Oncology 2 works
  6. 6 Nonmelanoma Skin Cancer Studies Epidemiology 1 works
  7. 7 Ubiquitin and proteasome pathways Molecular Biology 1 works
  8. 8 Nanoplatforms for cancer theranostics Biomedical Engineering 1 works
  9. 9 Cutaneous Melanoma Detection and Management Oncology 1 works
  10. 10 Histone Deacetylase Inhibitors Research Molecular Biology 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available52.5%not open47.5%

World: 40% of research is openly available.

with international co-authors16.8%domestic only83.2%

World: 18% is written across borders.

How has Phio Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 54% higher than in 2018-2021.

still counting20052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Phio Pharmaceuticals (United States) as a percentage of every work published that year, 0.00014% in 2024.

still counting0.000050%0.00010%0.00015%Phio Pharmaceuticals (United States)0.000064% in 202520102020

Fractional works of Phio Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Marlborough

All research institutions in Marlborough

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Phio Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.